Clinical trials: Placebo Group
Alopecia Areata
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata
This is a parallel, Phase 2 multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study to investigate the efficacy and safety of subcutaneous (SC) injections of amlitelimab treatment as monotherapy in…
- Trial name
- NCT06444451
- Testing
- Amlitelimab
- Where
- 74 sites in United States, Argentina and 14 more
- Volunteers
- 166 people
- Sponsor
- Sanofi
Insomnia
A Randomized, Double Blind, Parallel Group, Placebo Controlled, Multicenter Outpatient Trial Of PD 0200390 In Adults With Primary Insomnia
To demonstrate efficacy and characterize the dose response relationship of PD 0200390 on subjective wake after sleep onset in subjects with primary insomnia.
- Trial name
- NCT00569972
- Testing
- PD 0200390
- Where
- 84 sites in United States, Canada
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- Pfizer
Asthma With Eosinophilic Phenotype
A Study to Evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients With Eosinophil Phenotype
The purpose of this study is to evaluate the Pharmacodynamic, Efficacy and Safety of SHR-1703 in Asthma Patients with Eosinophil Phenotype.
- Trial name
- NCT05522439
- Testing
- SHR-1703
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Overactive Bladder, Detrusor Overactivity
A Study To Assess If 10 mg Vardenafil (BAY38-9456) Taken Twice Daily For 6 Weeks Has An Effect On Bladder Function
The purpose of this study is to assess if the study drug, Vardenafil (approved by Health Authorities is available on the market for treatment of erectile dysfunction) has an effect on bladder function and micturition frequency.
- Trial name
- NCT00478881
- Testing
- Vardenafil HCl (Levitra, BAY38-9456)
- Where
- 55 sites in Belgium, Canada and 11 more
- Volunteers
- 397 people
- Sponsor
- Bayer
Major Depressive Disorder
Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder
The purpose of the study is to evaluate the efficacy and the tolerability of three fixed doses of Vortioxetine in order to establish the appropriate clinical effective dose range in the treatment of Major Depressive Disorder…
- Trial name
- NCT00635219
- Testing
- Vortioxetine (Lu AA21004), Duloxetine
- Volunteers
- 766 people
- Sponsor
- H. Lundbeck A/S
Posterolateral Thoracotomy, Postoperative Pain
Intercostal Nerve Block With Liposome Bupivacaine in Subjects Undergoing Posterolateral Thoracotomy
The purpose of the study is to examine the safety and efficacy of liposome bupivacaine for intercostal nerve block in subjects undergoing posterolateral thoracotomy.
- Trial name
- NCT01802411
- Testing
- EXPAREL 266 mg
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 191 people
- Sponsor
- Pacira Pharmaceuticals, Inc
Diabetes, Diabetes Mellitus, Type 2
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment…
- Trial name
- NCT00696657
- Testing
- semaglutide, liraglutide
- Where
- 77 sites in Austria, Bulgaria and 12 more
- Volunteers
- 415 people
- Sponsor
- Novo Nordisk A/S
Community-acquired Pneumonia, Pneumonia
Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia
Multicenter double-blind placebo-controlled randomized in parallel groups clinical trial.
- Trial name
- NCT06263881
- Testing
- Raphamin
- Where
- 38 sites in Russia
- Volunteers
- 370 people
- Sponsor
- Materia Medica Holding
Obesity, Overweight
A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a…
- Trial name
- NCT06603571
- Testing
- LY3841136, Tirzepatide
- Where
- 52 sites in United States, Argentina
- Volunteers
- 367 people
- Sponsor
- Eli Lilly and Company
Migraine, Medication Overuse Headache
A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache
Medication overuse headache (MOH) is a type of headache caused by excessive use of acute headache or migraine medications (medications used to treat a headache or migraine once it begins).
- Trial name
- RESOLUTION (NCT05452239)
- Testing
- Eptinezumab
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 608 people
- Sponsor
- H. Lundbeck A/S
Triple Negative Breast Cancer
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in…
- Trial name
- NCT02032277
- Testing
- Cyclophosphamide, Doxorubicin, Paclitaxel
- Where
- 158 sites in United States, Australia and 13 more
- Volunteers
- 634 people
- Sponsor
- AbbVie
Warts
Topical 2% Povidone-Iodine Gel in Verruca Vulgaris
This is a multi-center, randomized, double-blind, placebo-controlled phase 2 study in subjects 8 years of age and older who present with verruca vulgaris (common warts) and desire treatment.
- Trial name
- NCT04253912
- Testing
- VBP-245
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Veloce BioPharma LLC
Depressive Disorder, Depression
GW679769 In Fibromyalgia
The purpose of the study is to investigate safety, tolerability and efficacy of oral GW679769 up to 120 mg dose compared to placebo in patients with ACR(American College of Rheumatology)-defined fibromyalgia, co-morbid with…
- Conditions
- Depressive Disorder, Depression, Fibromyalgia
- Trial name
- NCT00264628
- Testing
- GW679769
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal…
- Trial name
- NCT01382719
- Testing
- bremelanotide
- Where
- 68 sites in United States, Canada
- Volunteers
- 612 people
- Sponsor
- Palatin Technologies, Inc
Osteoporosis, Postmenopausal
Denosumab China Phase III Study
This study is to evaluate the efficacy and safety of denosumab 60 milligrams (mg) for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.
- Trial name
- NCT02014467
- Testing
- Denosumab, Elemental Calcium, Vitamin D
- Where
- 8 sites in China
- Volunteers
- 486 people
- Sponsor
- GlaxoSmithKline
Moderate-to-Severe Atopic Dermatitis
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
This is an interventional, randomized, parallel group, treatment, Phase 3, double blind study to assess the effect of Rezpegaldesleukin in participants 12 years of age or older with moderate to severe atopic dermatitis, as…
- Trial name
- ZENITH AD-1 (NCT07690371)
- Testing
- Rezpegaldesleukin
- Where
- 20 sites in United States
- Volunteers
- 510 people
- Sponsor
- Nektar Therapeutics
Group B Streptococcal Infections
A Phase 1/2, Randomized, Placebo-controlled, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Group B Streptococcus Vaccine In Healthy Adults 18 To 49 Years Of Age
This is the Phase 1/2 first-in-human, randomized, placebo-controlled, observer-blinded study evaluating the investigational multivalent group B streptococcus vaccine.
- Trial name
- NCT03170609
- Testing
- Multivalent group B streptococcus vaccine
- Where
- 4 sites in United States
- Volunteers
- 365 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetic Polyneuropathy
Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2)
To assess clinical efficacy and safety of long-term orally administered thioctic acid in the treatment of diabetic polyneuropathy.
- Trial name
- NATHAN1 (NCT00977483)
- Testing
- Thioctic Acid
- Where
- 38 sites in United States, Croatia and 7 more
- Volunteers
- 460 people
- Sponsor
- MEDA Pharma GmbH & Co. KG
Systemic Sclerosis-associated Interstitial Lung Disease
Abituzumab in SSc-ILD
The purpose of this trial was to compare two doses of abituzumab with placebo and determine whether abituzumab was more effective, safer, would be better tolerated and could provoke better immune response than placebo in the…
- Trial name
- NCT02745145
- Testing
- Abituzumab 1500 mg, Abituzumab 500 mg
- Where
- 55 sites in United States, Argentina and 7 more
- Volunteers
- 24 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Abdominal Pain
(Hyoscine Butylbromide) for Abdominal Pain Associated With Cramping on Demand Basis
The primary objective of this pilot study is to assess effects of Hyoscine Butylbromide (HBB) 20 mg in comparison to placebo, when used as needed, as measured by the subject's assessment of intensity of abdominal pain associated…
- Trial name
- NCT00932737
- Testing
- HBB 20 mg
- Where
- 19 sites in United States
- Volunteers
- 197 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.